Brendan Smith
Stock Analyst at TD Cowen
(2.21)
# 2,848
Out of 5,044 analysts
8
Total ratings
60%
Success rate
8.07%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Initiates: Buy | $350 | $283.49 | +23.46% | 1 | Oct 29, 2025 | |
| SLP Simulations Plus | Initiates: Hold | $16 | $18.31 | -12.62% | 1 | Sep 30, 2025 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $12.74 | -21.51% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $65.40 | -0.61% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $8.52 | +17.37% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $39.55 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $16.92 | - | 1 | Dec 5, 2022 |
West Pharmaceutical Services
Oct 29, 2025
Initiates: Buy
Price Target: $350
Current: $283.49
Upside: +23.46%
Simulations Plus
Sep 30, 2025
Initiates: Hold
Price Target: $16
Current: $18.31
Upside: -12.62%
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $12.74
Upside: -21.51%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $65.40
Upside: -0.61%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $8.52
Upside: +17.37%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $39.55
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $16.92
Upside: -